Research Analysts Offer Predictions for CRSP FY2025 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Chardan Capital lifted their FY2025 EPS estimates for CRISPR Therapeutics in a note issued to investors on Wednesday, May 7th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings per share of ($4.60) for the year, up from their prior forecast of ($4.62). Chardan Capital currently has a "Buy" rating and a $82.00 target price on the stock. The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share.

CRSP has been the subject of a number of other reports. Barclays lowered their target price on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a research note on Friday. The Goldman Sachs Group reduced their target price on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Evercore ISI upgraded CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and increased their price target for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $71.75.

CRISPR Therapeutics Trading Down 1.0%

NASDAQ CRSP traded down $0.37 on Monday, hitting $37.22. 2,024,125 shares of the company were exchanged, compared to its average volume of 1,668,717. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $67.88. The company has a market cap of $3.21 billion, a P/E ratio of -8.52 and a beta of 1.88. The firm has a 50 day moving average of $38.03 and a two-hundred day moving average of $42.64.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. CRISPR Therapeutics's revenue for the quarter was up 71.6% on a year-over-year basis. During the same quarter last year, the firm earned ($1.43) EPS.

Institutional Investors Weigh In On CRISPR Therapeutics

Several large investors have recently bought and sold shares of the company. Intellectus Partners LLC lifted its stake in CRISPR Therapeutics by 3.6% during the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock worth $281,000 after purchasing an additional 250 shares in the last quarter. Farrow Financial Inc. increased its holdings in CRISPR Therapeutics by 1.4% in the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock valued at $777,000 after buying an additional 270 shares in the last quarter. Kestra Private Wealth Services LLC increased its stake in shares of CRISPR Therapeutics by 1.5% during the 4th quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company's stock worth $812,000 after purchasing an additional 310 shares in the last quarter. SFE Investment Counsel increased its stake in shares of CRISPR Therapeutics by 5.8% during the 1st quarter. SFE Investment Counsel now owns 6,507 shares of the company's stock worth $221,000 after purchasing an additional 355 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in CRISPR Therapeutics by 7.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock valued at $215,000 after acquiring an additional 372 shares during the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 9,973 shares of the firm's stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $423,054.66. Following the completion of the transaction, the chief executive officer now owns 180,890 shares in the company, valued at $7,673,353.80. This trade represents a 5.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the transaction, the chief operating officer now owns 8,263 shares of the company's stock, valued at approximately $350,516.46. This represents a 12.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 32,381 shares of company stock worth $1,608,243 over the last ninety days. Company insiders own 4.30% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.